Pfizer Bets $480m On CStone And Surging China Immuno-Oncology Market
26% Annual IO Growth Forecast Alluring
The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.
